Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChina National Center for Cardiovascular Diseases

About this trial

Renal injury after cardiac surgery is one of the common complications with high incidence rate, high risk of death and progression to chronic kidney disease (CKD). Previous evaluations of perioperative renal function mainly focused on acute kidney injury (AKI) related to cardiac surgery within seven days after surgery. The newly proposed concept of acute kidney disease (AKD) in recent years refers to acute or subacute kidney injury lasting seven to ninety days. Research has found that AKD can occur after AKI or in patients without AKI, and the two are both related and independent of each other, possibly indicating different subtypes of kidney injury. AKD is not uncommon and is a more significant predictor of mortality and end-stage kidney disease (ESKD). Therefore, AKD may be an important window for identifying and managing high-risk patients after cardiac surgery. Due to limited research on AKD after cardiac surgery, the risk factors for AKD are currently unclear, and there are no clinically practical and effective risk stratification tools available. This study aims to establish a multimodal perioperative data platform through a retrospective cohort, and use machine learning methods to construct a risk prediction model for AKD after cardiac surgery. The accuracy and stability of the model will be validated in a prospective study cohort, and an online risk prediction and clinical decision-making tool will be developed to help clinicians quickly conduct personalized risk assessments and optimize diagnosis and treatment strategies, thereby improving patient prognosis and reducing medical costs.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years;

Undergoing coronary artery bypass grafting and/or heart valve surgery, with or without aortic surgery;

Baseline serum creatinine level < 354 umol/L;

Informed consent obtained.

Disqualifiers

Emergency surgery;

Multiple surgeries or reoperation;

End-stage kidney disease (ESKD), renal replacement therapy, or kidney transplantation;

Occurrence of AKI within 1 week before surgery or unresolved AKI;

Trial population

Inpatients undergoing cardiac surgery at Fuwai Hospital

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

820 Participants
are grouped into 1 trial group
Group A: Adult patients undergoing coronary artery bypass grafting and/or heart valve surgery

Trial outcomes

Primary outcomes

1

Number of Participants with acute kidney disease after cardiac surgery Assessed by KDIGO guideline

Time frame
within 90 days after cardiac surgery
2

acute kidney disease after cardiac surgery

Time frame
within 90 days after cardiac surgery

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: